Pfizer updated safety and efficacy results for its investigational compound CP-751,871 in patients with non-small cell lung cancer (NSCLC). Results from a Phase II, randomized, non-comparative study showed 54% of patients with Stage III/IV treatment-naïve NSCLC receiving the combination CP-751,871 plus carboplatin and paclitaxel experienced objective responses. The response rate was 41% in patients treated with carboplatin and paclitaxel alone.     Also, 78% of a subset of patients with squam...